Macular Edema and Macular Degeneration Market Research Explores Growth Within A $14.33 Billion Opportunity

The market for macular edema and macular degeneration is on track for significant expansion over the coming years, driven by various healthcare trends and advancements. Understanding the size, key players, emerging innovations, and market segments provides a valuable overview of this dynamic field focused on eye health.

Projected Growth Trajectory of the Macular Edema and Macular Degeneration Market
The macular edema and macular degeneration market is expected to achieve considerable growth by 2030, reaching a valuation of $14.33 billion. This growth will occur at a compound annual growth rate (CAGR) of 6.8%. The expansion is fueled by factors such as the increasing global diabetic population, heightened screening efforts for retinal diseases, a rising preference for minimally invasive eye treatments, broader availability of advanced ophthalmic care, and escalating healthcare expenditures focused on preserving vision. Key trends anticipated during this period include greater uptake of anti-VEGF therapies, heightened demand for early detection and treatment, more frequent use of combination drug and laser therapies, attention to diabetic eye complications, and growth in outpatient and clinic-based eye care services.

The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $10.33 billion in 2025 to $11.03 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing prevalence of diabetes and retinal disorders, aging population with higher vision impairment risk, clinical success of anti-vegf injections, growing awareness of macular diseases, expansion of ophthalmology clinics.

Download a free sample of the macular edema and macular degeneration market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Leading Companies Driving the Macular Edema and Macular Degeneration Market
Several prominent firms are shaping the macular edema and macular degeneration market landscape. These include F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bayer AG, AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co Ltd, Apellis Pharmaceuticals Inc., Alimera Sciences Inc., Kodiak Sciences Inc., Opthea Limited, IVERIC bio Inc., Neurotech Pharmaceuticals Inc., Regenxbio Inc., Graybug Vision Inc., Clearside Biomedical Inc., Kubota Pharmaceutical Holdings Co Ltd, Acucela Inc., PanOptica Inc., and Ocugen Inc.

Strategic Acquisition Enhancing the Market Portfolio
In July 2024, Merck and Co. Inc., a major US pharmaceutical and biotech company, acquired Eyebiotech Limited (Eyebio) for an undisclosed sum. This acquisition aims to bolster Merck's late-stage pipeline by incorporating Restoret, a promising candidate for treating diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD). The move enriches MSD's portfolio with novel treatments rooted in cutting-edge biology and genetics, addressing unmet needs in retinal disease therapeutics. Eyebiotech Limited is known for developing innovative therapies targeting sight-threatening eye conditions, including macular edema and macular degeneration.

View the full macular edema and macular degeneration market report:
https://www.thebusinessresearchcompany.com/report/macular-edema-and-macular-degeneration-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Innovations Shaping the Market Outlook
Key players in the macular edema and macular degeneration market are increasingly focusing on developing continuous-delivery ocular implants. These devices are designed to reduce the treatment burden on patients, enhance adherence to therapy, and provide more consistent long-term therapeutic benefits. Such implants are small, refillable devices implanted in the eye that release medication steadily over several months, thereby minimizing the frequency of injections required.

A notable example is the FDA approval received in February 2025 by F. Hoffmann-La Roche Ltd for Susvimo, a refillable ocular implant delivering the anti-VEGF drug ranibizumab to treat diabetic macular edema (DME). Susvimo offers a long-acting solution through a surgically implanted reservoir that continuously administers a customized formulation of ranibizumab. Unlike traditional monthly or bi-monthly anti-VEGF injections, this device allows for a refill-exchange interval of about six months. This sustained-delivery approach lowers treatment burden, improves patient compliance, streamlines clinical workflows, and delivers durable anatomical and visual improvements for patients with chronic retinal diseases.

Breakdown of Market Segments in the Macular Edema and Macular Degeneration Industry
The market report segments the macular edema and macular degeneration arena as follows:

1) By Treatment Type:
- Drug Therapy
- Laser Treatment

2) By Application:
- Macular Edema
- Diabetic Macular Edema (DME)
- Cystoid Macular Edema (CME)
- Macular Degeneration
- Dry Age-Related Macular Degeneration
- Wet Age-Related Macular Degeneration

3) By End User:
- Hospitals
- Clinics
- Other End Users

Further subcategories include:

- Drug Therapy: Anti-VEGF injections, steroid injections, and combination therapy (anti-VEGF plus steroids)
- Laser Treatment: focal laser photocoagulation, subthreshold laser therapy, and microPulse laser therapy

This detailed classification reflects the diverse treatment options and application scenarios shaping the market's development.

Our 2026 market reports now offer broader strategic coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.